Press Releases

– Jay S. Duker , M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Plan – WATERTOWN, Mass.

– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – –  Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass. , June 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.

WATERTOWN, Mass. , May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston , Chief Financial Officer of EyePoint

–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflection points WATERTOWN, Mass.

WATERTOWN, Mass. , May 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted

– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 – Enrollment ahead of schedule in the Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic

WATERTOWN, Mass. , April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at

WATERTOWN, Mass. , April 17, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock

- Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals - Topline DAVIO 2 data anticipated in Q4 2023 WATERTOWN, Mass. , March 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and

- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of retinal disease - - Clinical outcomes from real-world CALM registry study of YUTIQ ® demonstrates

– Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with enrollment completion anticipated in 4Q 2023 – – Net product revenues for Full Year 2022 of $39.9

WATERTOWN, Mass. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the

WATERTOWN, Mass. and NEW HAVEN, Conn. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation, a clinical-stage

WATERTOWN, Mass. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and

WATERTOWN, Mass. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted

– State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 – WATERTOWN, Mass. , Jan. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.

WATERTOWN, Mass. , Jan. 17, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted

– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR – – Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in

Dr. Duker has served as EyePoint’s Chief Operating Officer since November 2021 WATERTOWN, Mass. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with

WATERTOWN, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted